Oxford Drug Design, an advanced spinout from Oxford University, is an innovative biotechnology company discovering and developing novel therapeutics supported by pioneering computational methods. We are discovering new drugs with differentiated modes of action against challenging diseases with high unmet medical needs. Based on a core competence platform in tRNA synthetase enzymes and distinctive AI/ML methods, our pipeline expansion is focused on oncology. Our differentiated drug discovery platform has been validated by the rapid discovery of novel therapeutic candidates with highly innovative chemical scaffolds and modes of action against urgent pathogens.
The strong drug design and development expertise of Oxford Drug Design results from a distinctive combination of our two core competencies. Comprehensive capabilities in aminoacyl-tRNA synthetases (aaRS). Pioneering computational AI and machine learning methods. Each is distinctive in its own right, yet the seamless in-house integration of the two complementary strengths produces an even deeper and more differentiated capability.
Total Funding: N/A
Funding Stage: N/A
Business Stage: Scaling Up
Market: B2B
Company Size: 1 to 25
Founded: 2017
For AI/ML Startup Founders
Get introduced to VC/PE/CVC investors
For Investors at VC/PE firms
Get introduced to AI/ML Startup founders or founders at Oxford Drug Design
Alan Roth
Chief Executive Officer
Paul Finn
Chief Scientific Officer
Graham Richards
Chairperson